Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

Carl Zeiss Meditec AG, DE0005313704

Carl Zeiss Meditec AG, DE0005313704

16.07.2021 - 11:43:13

Carl Zeiss Meditec AG continues its growth after nine months 2020/21 and raises targets for fiscal year

? Carl Zeiss Meditec AG (ISIN: DE0005313704) has achieved revenue of EUR 1,198.2 million after nine months of fiscal year 2020/21 (past year: EUR 967.9 million). This corresponds to a revenue development of +23.8% vs. the past year (after adjustment for currency effects[1]: +27.6%). In the third quarter of FY 2020/21, revenue amounted to EUR 430.8 million (past year: EUR 253.0 million) - a growth rate of +70.3% (after adjustment for currency effects: +75.3%) against the previous year's period which had been heavily impacted by the COVID-19 pandemic. Revenue benefitted from a rise in recurring revenues as well as a further recovery in demand for equipment. Earnings before interest and taxes (EBIT)[2] amounted to EUR 282.8 million after nine months of FY 2020/21 (past year: EUR 111.9 million). EBIT margin (EBIT / revenue) was 23.6% (past year 11.6%). In the third quarter of FY 2020/21, EBIT amounted to EUR 120.1 million (past year: EUR 9.4 million). EBIT margin was 27.9% (past year: 3.7%). EBIT benefitted from a favorable development of product mix with a high share of recurring revenue. In addition, the ongoing low level of sales and marketing expenses as a result of the COVID-19 pandemic contributed to EBIT compared to the past year. Earnings per share (EPS)[3] amounted to EUR 2.04 (past year: EUR 0.77) for nine months of FY 2020/21. In the third quarter, EPS amounted to EUR 0.91 (past year: EUR 0.06). Full results for nine months 2020/21 will be published on August 6, 2021. In light of the positive business development, the company is raising targets for the current fiscal year 2020/21: revenue is expected to exceed the previous forecast of approximately EUR 1.6 billion (past year: EUR 1,335.5 million). EBIT margin for fiscal year 2020/21 is projected to significantly exceed the previous forecast of approximately 20% (past year: 13.3%), with strong support from lower than usual sales and marketing expenses in the current year. ? ?

?

Contact for investors and press Sebastian Frericks Head of Investor Relations Carl Zeiss Meditec AG Tel.: +49 3641 220-116 E-Mail: investors.meditec@zeiss.com

?

[1] Currency-adjusted revenue growth is determined by weighing sales in the comparative period with current instead of actual historical exchange rates.[2] Earnings before interest and taxes (also operating profit, EBIT) refers to a key earnings figure within the Carl Zeiss Meditec Group and is calculated in accordance with IFRS standards (see Annual Report 2019/20, p. 78 for reconciliation).[3] Earnings per share (also EPS) refers to a key earnings figure within the Carl Zeiss Meditec Group and is calculated according to IFRS standards (see Annual Report 2019/20, p. 78 for reconciliation).

16-Jul-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language: English Company: Carl Zeiss Meditec AG G?schwitzer Str. 51-52 07745 Jena, Germany

Germany Phone: +49 (0)3641 220-0 Fax: +49 (0)3641 220-112 E-mail: investors.meditec@zeiss.com Internet: www.zeiss.de/meditec-ag/ir ISIN: DE0005313704 WKN: 531370 Indices: MDAX, TecDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1219586 ? End of Announcement DGAP News Service

1219586??16-Jul-2021?CET/CEST

@ dgap.de